The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial
Open Access
- 6 December 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Public Health
- Vol. 12 (1), 1052
- https://doi.org/10.1186/1471-2458-12-1052
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Nanostructured and Spiky Gold Shell Growth on Magnetic Particles for SERS ApplicationsNanomaterials, 2020
- Nicotine Vaccines to Assist with Smoking CessationDrugs, 2012
- Vaccines against nicotineHuman Vaccines, 2009
- The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: Results of a randomized, placebo-controlled phase 1/2 trialNicotine & Tobacco Research, 2008
- Analysis of binary outcomes with missing data: missing = smoking, last observation carried forward, and a little multiple imputationAddiction, 2007
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- Revealing the multidimensional framework of the Minnesota nicotine withdrawal scaleCurrent Medical Research and Opinion, 2005
- Appraisal of the MedDRA Conceptual Structure for Describing and Grouping Adverse Drug ReactionsDrug Safety, 2005
- Antidepressants for smoking cessationPublished by Wiley ,2004
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991